ArticleLa Radiologia medica2025
Mining tumor and surrounding tissue information using artificial intelligence to predict responses to EGFR-targeted therapies and immunotherapy in lung cancer: a multicenter attribution analysis.
Article in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Human-AI Interaction in Interventional Radiology: A Narrative Review of Current Applications, Challenges, and Future Directions.Journal of imaging · 2026Review
- Radiogenomic landscape of the hallmarks of cancer.Biomarker research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn cancer therapy, tumor cell heterogeneity and dynamics influence gene sequencing and immunohistochemical staining. Importantly, patients treated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have not demonstrated a favorable long-term prognosis. Therefore, this study proposes an integrated framework for artificial intelligence (IFAI) to explore new molecular detection methods. MATERIALS AND
methodsOur study integrated data from 506 non-small cell lung cancer (NSCLC) patients across three institutions in China and the USA. To fuse radiomics scores and deep network features from both tumors and surrounding tissues, we developed the IFAI with an attention-based DenseNet 121 as the backbone network. We also explored the synergy between IFAI and clinical factors (IFAI-C). Additionally, we gained further insights into the biological mechanisms of IFAI by analyzing patient RNA sequencing data.
resultsIn independent test data, the IFAI-C demonstrated notable predictive performance, boasting an area under the curve of 0.912 for EGFR, 0.911 for exon 19 deletion (19Del), 0.905 for exon 21 mutation (L858R), 0.911 for T790M, and 0.904 for programmed cell death protein 1 (PD-1) or its ligand 1 (PD-L1). This capability is a crucial complement to traditional methods like gene sequencing and immunohistochemistry. Our analysis revealed that radiomics scores and deep network features in IFAI were significantly associated with EGFR genotypes, drug resistance mutations, and immune molecule expression. Furthermore, these features displayed robust connections with multiple genotypes associated with drug resistance and cancer progression mechanisms.
conclusionIFAI-C introduces a novel method with performance advantages, accompanied by biological analyses demonstrating the extraction of genotypic and immunomolecular information from both tumors and surrounding tissues. This discovery holds potential value in guiding therapeutic decisions for lung cancer.
Indexed as
Identifiers
41045354What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.